Patient Encounter 3 Part

Two years have passed. ET (now 62 years of age) has progressed to advanced neovas-cular AMD. His central vision continues to deteriorate and he recently gave up driving after several near-accidents. His wife and son help him with his daily routine now.

What treatment options does this patient have? What are the risks and benefits of each option?

Another drug, ranibizumab, binds to and inhibits the activity of VEGF-A, a critical

protein in angiogenesis. In one clinical study, 95% of patients treated with ranibizumab maintained visual acuity after 12 months compared with 62% of control pa-

tients. Both pegaptanib and ranibizumab are administered by intravitreous injec-

22 30 tion.22,J0

Beating Insomnia

Beating Insomnia

Discover How to Beat Insomnia Naturally & Enjoy a Great Night’s Sleep. The Secrets You Need to Know to Fall Asleep Fast, Sleep Through the Night & Awaken Feeling Rested, Refreshed and Rejuvenated.

Get My Free Ebook

Post a comment